A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas-Reference-Cited by-同舟云学术

A phase II trial of bendamustine in combination with ofatumumab in patients with relapsed or refractory marginal zone B‐cell lymphomas

Published:2020-11-06 Issue:1 Volume:39 Page:60-65
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Vannata Barbara¹^ORCID,Vanazzi Anna²,Negri Mara²,Liptrott Sarah Jayne²,Bartosek Anna Amalia³,Miani Monica³,Di Sanzo Alessandro³,Cavalli Franco¹⁴,Zucca Emanuele¹⁴^ORCID,Stathis Anastasios¹⁵

Affiliation:

1. Lymphoma Unit Oncology Institute of Southern Switzerland (IOSI) Bellinzona Switzerland

2. Division of Clinical Hemato‐Oncology European Institute of Oncology (IEO) IRCCS Milan Italy

3. Nerviano Medical Sciences S.r.l Nerviano Milan Italy

4. Faculty of Biomedical Sciences Institute of Oncology Research (IOR) Bellinzona Switzerland

5. Faculty of Biomedical Sciences Università della Svizzera italiana (USI) Lugano Switzerland

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2822

Reference33 articles.

1. Management of the marginal zone lymphomas;Vannata B;Cancer Treat Res,2015

2. The 2016 revision of the World Health Organization classification of lymphoid neoplasms

3. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma

4. Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

5. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Guideline for the diagnosis and management of marginal zone lymphomas: A British Society of Haematology Guideline;British Journal of Haematology;2023-11-13

2. The EHA Research Roadmap: Malignant Lymphoid Diseases;HemaSphere;2022-05-19